2020
Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane.
Scher H, Jendrisak A, Gill A, Barnett E, Gopalan A, Zaidi S, Benoliel H, Carbone E, Byun J, Schonhoft J, Wenstrup R. Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane. Journal Of Clinical Oncology 2020, 38: 5572-5572. DOI: 10.1200/jco.2020.38.15_suppl.5572.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen receptor signaling axisCirculating Tumor CellsPatients treated with platinumSmall-cell lung cancerCTC subtypesCastration-resistant prostate cancerCirculating tumor cells subtypesSmall-cell histologyPlatinum-based therapyAR protein expressionSmall-cell carcinomaAnalysis of circulating tumor cellsSmall-cell morphologyAnalytically validated assaysAssess drug activityLife-prolonging drugsCK+ cellsSmall cell/neuroendocrineTherapy linesOn-therapyProstate cancerPharmacodynamic changesTreated patientsTumor cells
2018
Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses’ Health Studies
Kensler KH, Poole EM, Heng YJ, Collins LC, Glass B, Beck AH, Hazra A, Rosner BA, Eliassen AH, Hankinson SE, Winer EP, Brown M, Tamimi RM. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses’ Health Studies. Journal Of The National Cancer Institute 2018, 111: 700-708. PMID: 30445651, PMCID: PMC6624168, DOI: 10.1093/jnci/djy173.Peer-Reviewed Original ResearchConceptsBreast cancer mortalityHealth Study II cohortNurses' Health StudyAR protein expressionCancer mortalityBreast cancerLog-linear associationAR expressionHealth StudyAndrogen receptorER- cancersHazard ratioNurses' Health Study II cohortCox proportional hazards modelProtein expressionInvasive breast cancerAndrogen receptor expressionBreast cancer survivalConfidence intervalsProportional hazards modelHormone receptor signalingPostmenopausal womenNegative tumorsWorse prognosisYears postdiagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply